Griñán Ferré, ChristianCodony Gisbert, SandraPujol Bech, EugèniaYang, JunLeiva Martínez, RosanaEscolano Mirón, CarmenPuigoriol Illamola, DolorsCompanys Alemany, JúliaCorpas Expósito, RubénSanfeliu i Pujol, CoralPérez, BelénLoza, María IsabelBrea, JoséMorisseau, ChristopheHammock, Bruce D.Vázquez Cruz, SantiagoPallàs i Llibería, Mercè, 1964-Galdeano Cantador, Carlos2021-03-112021-06-022020-06-021933-7213https://hdl.handle.net/2445/174895The inhibition of the enzyme soluble epoxide hydrolase (sEH) has demonstrated clinical therapeutic effects in several peripheral inflammatory-related diseases, with three compounds in clinical trials. However, the role of this enzyme in the neuroinflammation process has been largely neglected. Herein, we disclose the pharmacological validation of sEH as a novel target for the treatment of Alzheimer's Disease (AD). Evaluation of cognitive impairment and pathological hallmarks were used in two models of age-related cognitive decline and AD using three structurally different and potent sEH inhibitors as chemical probes. sEH is upregulated in brains from AD patients. Our findings supported the beneficial effects of central sEH inhibition, regarding reducing cognitive impairment, neuroinflammation, tau hyperphosphorylation pathology and the number of amyloid plaques. This study suggests that inhibition of inflammation in the brain by targeting sEH is a relevant therapeutic strategy for AD.application/pdfeng(c) American Society for Experimental NeuroTherapeutics, 2020Malaltia d'AlzheimerInflamacióMalalties neurodegenerativesAlzheimer's diseaseInflammationNeurodegenerative Diseasesinfo:eu-repo/semantics/article7007332021-03-11info:eu-repo/semantics/openAccess32488482